11 Best Healthcare ETFs To Buy Now

In this article, we discuss 11 best healthcare ETFs to buy now.

In 2023, the healthcare sector faced challenges as investors adjusted portfolios in anticipation of higher interest rates. Although the sector lagged behind others like technology and communication services, there were opportunities for significant growth. As per BlackRock’s latest report, within the pharmaceutical sub-sector, performance varied widely. Notably, GLP-1 drugs emerged as effective weight loss treatments, boosting leading developers Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO). However, many companies struggled due to tough year-over-year comparisons after revenue from vaccines and therapeutics surged past $100 billion in 2022 amid the COVID-19 pandemic. In the medical device and supplies sector, easing supply constraints and a return to elective procedures led to 7% returns by August 1, 2023. However, an announcement by Novo Nordisk A/S (NYSE:NVO) regarding cardiovascular benefits in their GLP-1 SELECT trial triggered a sell-off, erasing gains and resulting in negative returns for the sub-sector. Biotechnology faced continued pressure as interest rates rose, with several indices nearing multi-year lows. Providers and services also felt the impact of COVID-19 aftershocks, with utilization trends and rising medical costs remaining concerns. However, distributors saw improvements in fundamentals and the resolution of opioid litigation issues.

The global healthcare sector faces another year of significant change and challenges in 2024. Providers worldwide are grappling with ongoing labor shortages and rising costs stemming from the lingering effects of the COVID-19 pandemic. However, there is optimism fueled by the broader adoption of technologies like artificial intelligence, which hold promise in addressing some of these issues. Despite this, the ongoing existence of health disparities poses additional challenges and financial burdens for the healthcare sector in 2024. If not adequately tackled, Deloitte forecasts that these inequities could lead to a threefold increase in costs, reaching $1 trillion by 2040, equating to roughly US$3,000 annually per individual.

On a positive note, the integration of AI and machine learning technologies offers potential solutions to these disparities, provided providers address trust and bias issues. Moreover, the pandemic accelerated the adoption of remote technologies and telemedicine, transforming the delivery and nature of healthcare. Providers are extending care beyond traditional medical services to include holistic social care, recognizing the profound impact of social determinants on overall well-being. Consequently, there is a push to integrate social care into public health systems to address multifaceted patient needs. Moreover, addressing the escalating costs of healthcare remains a priority globally, with efforts focused on controlling costs while maintaining quality and accessibility. Strategies such as value-based care models and innovative pricing structures aim to ensure cost-effective healthcare delivery.

According to KPMG, on the pharmaceutical side, notable policy shifts by the Federal Trade Commission (FTC) and the Biden administration posed challenges alongside innovations in precision medicine. Diagnostics saw a decline in domestic mergers and acquisitions, with significant transactions involving international entities. Conversely, the medical devices sector anticipates recovery following a resurgence in elective surgeries and advancements in areas like cardiology and robotic surgery. Biopharma services continue to adapt post-COVID-19, with demand fluctuating and competition intensifying. Hospitals and health systems are focusing on efficiency and revenue enhancement through automation and strategic partnerships. Physician practices witnessed increased interest from strategic buyers, particularly in the latter half of 2023, amidst reimbursement pressures and regulatory changes. Lastly, healthcare IT, though fragmented, is witnessing a shift towards digital transformation, driving potential deal activity.

Some of the best healthcare stocks to buy include Danaher Corporation (NYSE:DHR), Thermo Fisher Scientific Inc. (NYSE:TMO), and AbbVie Inc. (NYSE:ABBV). However, we discuss the best healthcare ETFs in this article. 

Our Methodology 

We curated our list of the best healthcare ETFs by choosing consensus picks from multiple credible websites. We have mentioned the 5-year share price performance of each ETF as of March 19, 2024, ranking the list in ascending order of the share price. We have also discussed the top holdings of the ETFs to offer better insight to potential investors. 

A healthcare provider holding an MRI scan of a patient with a traumatic brain injury.

Best Healthcare ETFs To Buy Now

11. iShares U.S. Pharmaceuticals ETF (NYSE:IHE)

5-year Share Price Performance as of March 19: 31.32%

iShares U.S. Pharmaceuticals ETF (NYSE:IHE) aims to mirror the performance of the Dow Jones U.S. Select Pharmaceuticals Index, which contains American pharmaceutical equities. It offers exposure to companies involved in producing prescription or over-the-counter medications and vaccines. As of March 18, 2024, iShares U.S. Pharmaceuticals ETF (NYSE:IHE) holds $654.5 million in net assets with an expense ratio of 0.40%. Its portfolio comprises 35 stocks and the ETF was founded on May 1, 2006. iShares U.S. Pharmaceuticals ETF (NYSE:IHE) is one of the best healthcare ETFs to buy. 

Johnson & Johnson (NYSE:JNJ) is the largest holding of the iShares U.S. Pharmaceuticals ETF (NYSE:IHE). Johnson & Johnson (NYSE:JNJ) surpassed Wall Street expectations with its Q4 2023 results. The outperformance was attributed to its pharma and MedTech segments following the separation of its consumer care division Kenvue. The company reported sales of $21.4 billion for Q4 and $85.2 billion for the full year, with year-over-year growth rates of 7.3% and 6.5%, respectively.

According to Insider Monkey’s fourth quarter database, 81 hedge funds were long Johnson & Johnson (NYSE:JNJ), compared to 84 funds in the prior quarter. Ken Fisher’s Fisher Asset Management is the largest stakeholder of the company, with 6.35 million shares worth $995.3 million. 

Like Danaher Corporation (NYSE:DHR), Thermo Fisher Scientific Inc. (NYSE:TMO), and AbbVie Inc. (NYSE:ABBV), Johnson & Johnson (NYSE:JNJ) is one of the best healthcare stocks to buy.

ClearBridge Large Cap Value Strategy made the following comment about Johnson & Johnson (NYSE:JNJ) in its Q3 2023 investor letter:

“The healthcare space provided some opportunities in the quarter, as we increased our exposure to medical device company Becton, Dickinson as well as large cap pharmaceutical company Johnson & Johnson (NYSE:JNJ). Johnson & Johnson recently spun out its consumer health care business, becoming a more focused yet broadly diversified pharmaceutical and medtech company.”

10. First Trust Health Care AlphaDEX Fund (NYSE:FXH)

5-year Share Price Performance as of March 19: 41.14%

First Trust Health Care AlphaDEX Fund (NYSE:FXH) is one of the best healthcare ETFs to buy. First Trust Health Care AlphaDEX Fund (NYSE:FXH) is designed to match the performance of the StrataQuant Health Care Index. Established on May 5, 2007, its objective is to achieve results corresponding to the index’s price and yield, before fees and expenses. As of March 18, 2024, First Trust Health Care AlphaDEX Fund (NYSE:FXH) holds net assets totaling $1.30 billion with a net expense ratio of 0.62%. Its portfolio consists of 85 stocks. 

Natera, Inc. (NASDAQ:NTRA) is the largest holding of First Trust Health Care AlphaDEX Fund (NYSE:FXH). Natera, Inc. (NASDAQ:NTRA) is a global diagnostics company specializing in molecular testing services. Their products cover prenatal screening, carrier screening, single-gene disorders, preimplantation genetic testing, cancer detection, and organ transplant rejection assessment. On February 28, Natera reported a Q4 GAAP EPS of -$0.65 and a revenue of $311.1 million, outperforming Wall Street estimates by $0.06 and $23.78 million, respectively. 

According to Insider Monkey’s fourth quarter database, 50 hedge funds were long Natera, Inc. (NASDAQ:NTRA), compared to 49 funds in the prior quarter. 

Alger Weatherbie Specialized Growth Fund stated the following regarding Natera, Inc. (NASDAQ:NTRA) in its fourth quarter 2023 investor letter:

“Natera, Inc. (NASDAQ:NTRA) is a specialty lab providing genetic testing services in the reproductive health, oncology and transplant markets. Reproductive health tests are run to screen for common genetic disorders such as trisomy 13, 18. and 21 in pregnant women these tests are also known as non-invasive prenatal testing (NIPT) The company’s oncology franchise is led by Signatera, a test used to detect minimal residual disease (MRD) the applications of this test are primarily to monitor therapy response and detect cancer recurrence Lastly Natera s transplant franchise is led by Prospera, a test used to monitor transplant organ rejection, Natera’s tests are all based on the company’s proprietary liquid biopsy platform to detect cell-free DNA. During the quarter, shares contributed to performance primarily driven by strong fiscal third quarter results. Specifically. better-than-expected fiscal third quarter revenue, Signatera test volume, and gross margins all came in above analyst estimates, which led to management increasing their fiscal full year guidance.”

9. VanEck Pharmaceutical ETF (NASDAQ:PPH)

5-year Share Price Performance as of March 19: 47.54%

VanEck Pharmaceutical ETF (NASDAQ:PPH) ranks 9th on our list of the best healthcare ETFs. VanEck Pharmaceutical ETF (NASDAQ:PPH) aims to mirror the MVIS US Listed Pharmaceutical 25 Index, which includes companies engaged in different aspects of the pharmaceutical industry. As of March 18, 2024, the ETF holds net assets worth $547.82 million, with an expense ratio of 0.36% and a portfolio comprising 26 stocks. VanEck Pharmaceutical ETF (NASDAQ:PPH) was established on December 20, 2011. 

Eli Lilly and Company (NYSE:LLY) is the largest holding in VanEck Pharmaceutical ETF (NASDAQ:PPH)’s portfolio. On February 6, Eli Lilly and Company (NYSE:LLY) reported a Q4 non-GAAP EPS of $2.49 and a revenue of $9.35 billion, exceeding Wall Street estimates by $0.12 and $380 million, respectively. 

According to Insider Monkey’s fourth quarter database, 102 hedge funds were bullish on Eli Lilly and Company (NYSE:LLY), same as the prior quarter. Ken Fisher’s Fisher Asset Management is the largest stakeholder of the company, with 4.5 million shares worth $2.6 billion. 

Aristotle Atlantic Core Equity Strategy stated the following regarding Eli Lilly and Company (NYSE:LLY) in its fourth quarter 2023 investor letter:

“Eli Lilly and Company (NYSE:LLY) is a leading pharmaceutical company that develops diabetes, oncology, immunology and neuroscience medicines. The company generates over half of its revenue in the U.S. from its top-selling drugs Trulicity, Verzenio and Taltz. The company operates in a single business segment, Human pharmaceutical products.

Eli Lilly has a deep pipeline in treatment areas focused on metabolic disorders, oncology, immunology and central nervous system disorders. Currently, there are two phase three assets, Orforglipron, an oral GLP-1 and retatrutide, a triple incretin agonist, which have the potential to expand upon the potential success of Mounjaro. We believe that Mounjaro has the potential to commercialize beyond type 2 diabetes and obesity, potentially in the areas mentioned above of heart disease, sleep apnea, fatty liver disease and chronic kidney disease. We believe the premium valuation is supported by this outsized growth profile.”

8. iShares U.S. Medical Devices ETF (NYSE:IHI)

5-year Share Price Performance as of March 19: 50.67%

iShares U.S. Medical Devices ETF (NYSE:IHI) aims to mirror the performance of the Dow Jones U.S. Select Medical Equipment Index, which includes US medical device sector equities. As of March 18, 2024, the ETF holds $5.60 billion in net assets, with a portfolio of 52 stocks and an expense ratio of 0.40%. iShares U.S. Medical Devices ETF (NYSE:IHI), established on May 1, 2006, is one of the best healthcare ETFs. 

Abbott Laboratories (NYSE:ABT) is the top holding of iShares U.S. Medical Devices ETF (NYSE:IHI). Abbott Laboratories (NYSE:ABT) is a global healthcare company that specializes in discovering, developing, manufacturing, and selling healthcare products worldwide. On February 16, the company declared a $0.55 per share quarterly dividend, in line with previous. The dividend is payable on May 15, to shareholders on record as of April 15. 

According to Insider Monkey’s fourth quarter database, 64 hedge funds were bullish on Abbott Laboratories (NYSE:ABT), compared to 69 funds in the prior quarter. 

Polen Global Growth Strategy stated the following regarding Abbott Laboratories (NYSE:ABT) in its fourth quarter 2023 investor letter:

“Abbott Laboratories (NYSE:ABT), a globally dominant healthcare business serving a broad range of end markets, was another position we added to in the period. The stock has come under pressure in recent quarters as the company has experienced a significant (and expected) decline in sales tied to pandemic-era COVID testing. However, we feel this amounts to little more than a distraction, as the core business continues to perform very well. Nothing has changed around our expectations for long-term growth, yet the stock’s valuation has compressed, making for an attractive opportunity to add to the position given the long-term durable growth profile of this business.”

7. iShares Global Healthcare ETF (NYSE:IXJ)

5-year Share Price Performance as of March 19: 51.85%

iShares Global Healthcare ETF (NYSE:IXJ) ranks 7th on our list of the best healthcare ETFs. iShares Global Healthcare ETF (NYSE:IXJ) aims to replicate the performance of the S&P Global 1200 Healthcare Sector Index, comprising global equities in the healthcare sector, including pharmaceutical, biotechnology, and medical device companies. As of March 18, 2024, the fund holds net assets of $4 billion, featuring an expense ratio of 0.42% and a portfolio comprising 113 stocks. 

UnitedHealth Group Incorporated (NYSE:UNH), a diversified American healthcare company, is one of the top holdings of the iShares Global Healthcare ETF (NYSE:IXJ).  UnitedHealth Group Incorporated (NYSE:UNH) paid a $1.88 per share quarterly dividend to shareholders on March 19. 

According to Insider Monkey’s fourth quarter database, 113 hedge funds were bullish on UnitedHealth Group Incorporated (NYSE:UNH), compared to 104 funds in the prior quarter. Rajiv Jain’s GQG Partners is the biggest stakeholder of the company, with 3.4 million shares worth $1.80 billion. 

Wedgewood Partners stated the following regarding UnitedHealth Group Incorporated (NYSE:UNH) in its fourth quarter 2023 investor letter:

“UnitedHealth Group Incorporated (NYSE:UNH) contributed less to portfolio performance than the majority of our holdings during the quarter. The Company reported double-digit revenue, operating earnings and earnings per share growth during their third quarter. The Company has been able to adjust pricing in its health care segment to keep up with medical cost inflation while working with its Optum units to deliver more value-based care that replaces the traditional fee for service health care model. Value-based care is a sensible, long-term growth opportunity for the Company to pursue and also differentiates it from the vast majority of healthcare providers, particularly as it relates to Medicare patients. For example, the Company’s value-based care programs provide more preventative care opportunities and home-based care visits for patients which helps save the U.S. healthcare system billions in unnecessary spending while also providing patients with better outcomes, as diseases and behaviors are caught or corrected at earlier stages. The Company has invested in several core assets over many years to execute this value-based strategy and it will become the standard of care as the proportion of people in the U.S. with healthcare insurance coverage continues to reach new highs.”

6. Fidelity MSCI Health Care Index ETF (NYSE:FHLC)

5-year Share Price Performance as of March 19: 55.30%

Fidelity MSCI Health Care Index ETF (NYSE:FHLC) is one of the best healthcare ETFs. Fidelity MSCI Health Care Index ETF (NYSE:FHLC) aims to replicate the performance of the MSCI USA IMI Health Care 25/50 Index, which covers large, mid, and small-cap segments of the American healthcare industry. The fund holds $3,032.0 million in assets as of December 31, 2023, with an expense ratio of 0.084% and a portfolio comprising 370 stocks. The fund was established on October 21, 2013. 

Fidelity MSCI Health Care Index ETF (NYSE:FHLC)’s top holdings include Merck & Co., Inc. (NYSE:MRK). On February 1, Merck & Co., Inc. (NYSE:MRK) reported a Q4 non-GAAP EPS of $0.03 and a revenue of $14.6 billion, outperforming Wall Street estimates by $0.14 and $120 million, respectively. 

According to Insider Monkey’s fourth quarter database, 98 hedge funds held stakes in Merck & Co., Inc. (NYSE:MRK), up from 85 funds in the last quarter. Ken Fisher’s Fisher Asset Management is the largest stakeholder of the company, with 13.5 million shares worth nearly $1.5 billion. 

In addition to Danaher Corporation (NYSE:DHR), Thermo Fisher Scientific Inc. (NYSE:TMO), and AbbVie Inc. (NYSE:ABBV), Merck & Co., Inc. (NYSE:MRK) is one of the best healthcare stocks to invest in. 

Carillon Eagle Mid Cap Growth Fund made the following comment about Merck & Co., Inc. (NYSE:MRK) in its Q3 2023 investor letter:

“Merck & Co., Inc. (NYSE:MRK) underperformed in the third quarter, based on what we view as largely macroeconomic-related factors. The company continues to execute well, both clinically and fundamentally, but much of the biopharmaceutical industry has been weak as investors are gravitating to other, more cyclical sectors.”

5. Vanguard Health Care Index Fund ETF Shares (NYSE:VHT)

5-year Share Price Performance as of March 19: 55.83%

Vanguard Health Care Index Fund ETF Shares (NYSE:VHT) aims to mirror the performance of the Spliced U.S. Investable Market Health Care 25/50 Index, which measures the investment return of stocks in the health care sector. The ETF utilizes a passive management approach, employing a full-replication strategy when possible and a sampling strategy when regulatory constraints dictate. As of February 29, 2024, Vanguard Health Care Index Fund ETF Shares (NYSE:VHT)’s expense ratio is 0.10%, with net assets totaling $20.8 billion and a portfolio comprising 414 stocks. Vanguard Health Care Index Fund ETF Shares (NYSE:VHT) is one of the best healthcare stocks to buy.

AbbVie Inc. (NYSE:ABBV) is one of the top holdings of Vanguard Health Care Index Fund ETF Shares (NYSE:VHT). On February 15, AbbVie Inc. (NYSE:ABBV) declared a $1.55 per share quarterly dividend, in line with previous. The dividend is distributable on May 15, to shareholders on record as of April 15. 

According to Insider Monkey’s fourth quarter database, 76 hedge funds were bullish on AbbVie Inc. (NYSE:ABBV), compared to 73 funds in the last quarter. Paul Marshall and Ian Wace’s Marshall Wace LLP is a prominent stakeholder of the company, with 3.17 million shares worth nearly $492 million. 

4. iShares U.S. Healthcare Providers ETF (NYSE:IHF)

5-year Share Price Performance as of March 19: 57.06%

iShares U.S. Healthcare Providers ETF (NYSE:IHF) ranks 4th on our list of the best healthcare ETFs. iShares U.S. Healthcare Providers ETF (NYSE:IHF) aims to replicate the performance of the Dow Jones U.S. Select Healthcare Providers Index, consisting of U.S. equities in the healthcare providers sector. It offers exposure to companies in the United States providing health insurance, diagnostics, and specialized treatment. As of March 18, 2024, iShares U.S. Healthcare Providers ETF (NYSE:IHF) holds net assets totaling $836 million with an expense ratio of 0.40%. Its portfolio consists of 67 stocks. 

Elevance Health, Inc. (NYSE:ELV) is one of the top holdings of the iShares U.S. Healthcare Providers ETF (NYSE:IHF). Elevance Health, Inc. (NYSE:ELV) is a health benefits company operating in the United States through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. On January 30, the company declared a quarterly dividend of $1.63 per share quarterly dividend, a 10.1% increase from its prior dividend of $1.48. The dividend is payable on March 22, to shareholders on record as of March 8. 

According to Insider Monkey’s fourth quarter database, 83 hedge funds were bullish on Elevance Health, Inc. (NYSE:ELV), same as the prior quarter. Jean-Marie Eveillard’s First Eagle Investment Management is the leading stakeholder of the company, with 1.7 million shares worth $838.6 million. 

ClearBridge Large Cap Value Strategy made the following comment about Elevance Health, Inc. (NYSE:ELV) in its Q3 2023 investor letter:

“Our health care positioning also fared well. We continue to maintain an overweight position to managed care companies via long-term holdings in UnitedHealth and Elevance Health, Inc. (NYSE:ELV), as we believe the short cycle nature of their insurance franchises allows them to reprice their book of business in a relatively short time frame, even if health care costs come in higher than previously anticipated.”

3. iShares U.S. Healthcare ETF (NYSE:IYH)

5-year Share Price Performance as of March 19: 59.06%

iShares U.S. Healthcare ETF (NYSE:IYH) aims to replicate the performance of the Russell 1000 Health Care RIC 22.5/45 Capped Gross Index, which provides exposure to healthcare equipment and services, pharmaceuticals, and biotechnology companies in the United States. As of March 18, 2024, the ETF holds nearly $3.5 billion in net assets, with an expense ratio of 0.40%, and a portfolio consisting of 112 stocks. iShares U.S. Healthcare ETF (NYSE:IYH) ranks 3rd on our list of the best healthcare ETFs. 

Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the largest holdings of the iShares U.S. Healthcare ETF (NYSE:IYH). Thermo Fisher is a global provider of life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and services. On February 21, Thermo Fisher Scientific Inc. (NYSE:TMO) declared a $0.39 per share quarterly dividend, an 11.4% increase from its prior dividend of $0.35. The dividend is payable on April 15, to shareholders on record as of March 15. 

According to Insider Monkey’s fourth quarter database, 111 hedge funds were bullish on Thermo Fisher Scientific Inc. (NYSE:TMO), compared to 109 funds in the prior quarter. Chris Hohn’s TCI Fund Management is the leading stakeholder of the company, with 3.14 million shares worth $1.67 billion. 

Weitz Partners III Opportunity Fund made the following comment about Thermo Fisher Scientific Inc. (NYSE:TMO) in its second quarter 2023 investor letter:

“Portfolio activity this quarter included opportunistically initiating a position in life sciences tool and equipment maker Thermo Fisher Scientific Inc. (NYSE:TMO), a long-time holding of other Weitz portfolios, at an attractive valuation.”

2. Health Care Select Sector SPDR Fund (NYSE:XLV)

5-year Share Price Performance as of March 19: 59.81%

Health Care Select Sector SPDR Fund (NYSE:XLV) aims to match the performance of the Health Care Select Sector Index. This index represents the health care sector of the S&P 500 Index and includes companies from pharmaceuticals, health care equipment and supplies, health care providers and services, biotechnology, life sciences tools and services, and health care technology industries. The ETF features an expense ratio of 0.09% as of March 19, 2024, with a portfolio comprising 64 stocks. Its assets under management as of the same date totaled $40,644.38 million. Health Care Select Sector SPDR Fund (NYSE:XLV) is one of the best healthcare ETFs to buy. 

Danaher Corporation (NYSE:DHR) is one of the top holdings of Health Care Select Sector SPDR Fund (NYSE:XLV). Danaher designs, manufactures, and markets professional, medical, industrial, and commercial products and services. It operates through Biotechnology, Life Sciences, and Diagnostics segments. On February 22, Danaher Corporation (NYSE:DHR) declared a $0.27 per share quarterly dividend, a 12.5% increase from its prior dividend of $0.24. The dividend is payable on April 26, to shareholders on record as of March 28. 

According to Insider Monkey’s fourth quarter database, Danaher Corporation (NYSE:DHR) was part of 90 hedge fund portfolios, compared to 103 in the last quarter. 

Headwaters Capital Management stated the following regarding Danaher Corporation (NYSE:DHR) in its fourth quarter 2023 investor letter:

“Danaher Corporation’s (NYSE:DHR) acquisition offer for ABCM was approved by shareholders on 11/6/23. Shareholders approved the deal based on trough fundamentals (potential China weakness) and trough valuation (the broader market bottomed on 10/27). DHR took advantage of broader market fears and mis-aligned management incentives to acquire Abcam at a cheap price. While disappointing, ABCM was still a very successful investment for Headwaters as it outperformed the market by +27% during our ownership. The cash received from the acquisition was immediately re-deployed into the newest addition to the portfolio, IPAR (discussed below).”

1. Invesco S&P 500 Equal Weight Health Care ETF (NYSE:RSPH)

5-year Share Price Performance as of March 19: 59.94%

Invesco S&P 500 Equal Weight Health Care ETF (NYSE:RSPH) tracks the S&P 500 Equal Weight Health Care Index, which equally weights stocks in the healthcare sector of the S&P 500. The fund and index are rebalanced quarterly. Launched on November 1, 2006, the ETF features an expense ratio of 0.40% and holds a portfolio of 66 stocks as of March 18, 2024. Invesco S&P 500 Equal Weight Health Care ETF (NYSE:RSPH) is one of the best stocks to buy. 

West Pharmaceutical Services, Inc. (NYSE:WST) is the largest holding of the Invesco S&P 500 Equal Weight Health Care ETF (NYSE:RSPH). West Pharmaceutical Services, Inc. (NYSE:WST) specializes in designing, manufacturing, and selling containment and delivery systems for injectable drugs and healthcare products globally. On February 20, the company declared a $0.20 per share quarterly dividend, in line with previous. The dividend is payable on May 1, to shareholders on record as of April 24. 

According to Insider Monkey’s fourth quarter database, 42 hedge funds were long West Pharmaceutical Services, Inc. (NYSE:WST), same as the prior quarter. 

Conestoga Capital Advisors SMid Cap Strategy stated the following regarding West Pharmaceutical Services, Inc. (NYSE:WST) in its fourth quarter 2023 investor letter:

“West Pharmaceutical Services, Inc. (NYSE:WST)): WST, a market leader in containment and delivery solutions for the pharmaceutical industry, posted a strong 2023 but gave back some gains during the fourth quarter. During their third quarter call, WST reduced full-year revenue guidance as restocking in its Pharmaceutical and Generics end markets have slowed below expectations. Despite the reduction, ex-COVID revenues continue to grow double-digits and WST reiterated their expectation for 7-9% organic growth in 2024 with 100 basis points of margin expansion, in line with their long-term model.”

Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily enewsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below. You can also check out 12 Best Bond ETFs To Buy and 11 Best Dividend ETFs To Buy. 

Suggested articles:

• 11 Best Energy ETFs: Top Oil, Gas and Renewable Energy Funds
• 10 Best Gold ETFs To Buy Now
• 10 Best Commodity ETFs

Disclosure: None. 11 Best Healthcare ETFs To Buy Now is originally published on Insider Monkey.